MYC and colorectal carcinoma: Several studies showed that when upregulated, c-MYC activates mitogen-activated protein kinase (MAPK) and rat sarcoma (RAS) signaling, which eventually alters the response to oxaliplatin or vorinostat treatment in breast cancer and CRC patients [20,21].